

Ref: FOIA Reference 2022/23-401

Date: 7th November 2022

Email foi@uhn.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 19th October 2022 requesting information under the Freedom of Information Act (2000) regarding Melanoma & RCC.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I have a freedom of information request regarding the treatment of renal cell carcinoma and melanoma. Could you please answer the following questions?

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma?

- **Avelumab + Axitinib**
- **Axinitib**
- **Cabozantinib**
- **Everolimus**
- **Lenvatinib + Everolimus**
- **Nivolumab**
- **Nivolumab + Cabozantinib**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Pembrolizumab + Axitinib**
- **Pembrolizumab + Lenvatinib**
- **Pembrolizumab monotherapy**
- **Radiotherapy only**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI

Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Avelumab + Axitinib = 5
- Axinitib = <5
- Cabozantinib = 10
- Everolimus = 0
- Lenvatinib + Everolimus = <5
- Nivolumab = 6
- Nivolumab + Cabozantinib = 0
- Nivolumab + Ipilimumab = 9
- Pazopanib = <5
- Pembrolizumab + Axitinib = 0
- Pembrolizumab + Lenvatinib = 0
- Pembrolizumab monotherapy = 0
- Radiotherapy only
- Sunitinib = <5
- Temsirolimus = 0
- Tivozanib = 9
- Other active systemic anti-cancer therapy = 0
- Palliative care only - data not held for patients on Best Supportive Care, as not on active SACT (Systemic Anti-Cancer Therapy)

Q2 How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- **Cobimetinib**
- **Dabrafenib**
- **Dabrafenib AND Trametinib**
- **Dacarbazine**
- **Encorafenib AND Binimetinib**
- **Ipilimumab**
- **Ipilimumab AND Nivolumab**
- **Nivolumab**
- **Pembrolizumab**
- **Trametinib**
- **Vemurafenib**
- **Vemurafenib AND Cobimetinib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- . Cobimetinib = 0
- . Dabrafenib = 0
- . Dabrafenib AND Trametinib = 12
- . Dacarbazine = <5
- . Encorafenib AND Binimetinib = <5
- . Ipilimumab = 0
- . Ipilimumab AND Nivolumab = 13
- . Nivolumab = <5
- . Pembrolizumab = 32
- . Trametinib = 0
- . Vemurafenib = 0
- . Vemurafenib AND Cobimetinib = 0
- . Other active systemic anti-cancer therapy = 0
- . Palliative care only - data not held for patients on Best Supportive Care, as not on active SACT (Systemic Anti-Cancer Therapy)

Q3 If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- . **Cobimetinib**
- . **Dabrafenib**
- . **Dabrafenib AND Trametinib**
- . **Dacarbazine**
- . **Encorafenib AND Binimetinib**
- . **Ipilimumab**
- . **Ipilimumab AND Nivolumab**
- . **Nivolumab**
- . **Pembrolizumab**
- . **Trametinib**
- . **Vemurafenib**
- . **Vemurafenib AND Cobimetinib**
- . **Other active systemic anti-cancer therapy**
- . **Palliative care only**

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- . Cobimetinib = 0
- . Dabrafenib = 0
- . Dabrafenib AND Trametinib = 12
- . Dacarbazine = <5
- . Encorafenib AND Binimetinib = <5
- . Ipilimumab = 0
- . Ipilimumab AND Nivolumab = 12
- . Nivolumab = <5
- . Pembrolizumab = 27

- Trametinib = 0
- Vemurafenib = 0
- Vemurafenib AND Cobimetinib = 0
- Other active systemic anti-cancer therapy = 0
- Palliative care only - data not held for patients on Best Supportive Care, as not on active SACT (Systemic Anti-Cancer Therapy)

Q4 In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

A4 For the period 01/07/22 to 30/09/22 there were 28 patients who underwent either a full or partial nephrectomy (just to clarify we have used the OPCS codes as supplied above).

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



Leah Carlisle
Head of Data, Security & Protection/ Data Protection Officer